Categories: Stock Market

Ford Motor stock downgraded at CFRA on valuation, EV production ramp-up issues By Investing.com


© Reuters. Ford Motor (F) stock downgraded at CFRA on valuation, EV production ramp-up issues

CFRA analysts lowered their recommendation on Ford Motor (NYSE:) stock to Hold with the price target of $16 per share still maintained.

Ford reported a 16.1% increase in U.S. auto sales for the last month, pushing the total Q2 sales to 531,662 units, up 9.9% year-over-year. The Q2 car sales performance was better than expected as analysts were looking for sales of 524,000.

However, the analysts flag “sluggish” F-150 Lightening production numbers with Q2 sales of this popular EV model up just 4% compared to Q1.

“We think EV production ramp-up issues are likely to be widespread among traditional automakers as they attempt to execute aggressive growth plans. After a 30% YTD run-up for the stock, we lower our rating to Hold, but continue to view Ford’s dividend yield as compelling,” they added in a note.

Ford stock fell 2.4% on Thursday.

 

Source link

nasdaqpicks.com

Share
Published by
nasdaqpicks.com

Recent Posts

Gains of green economy – The Hindu BusinessLine

The Budget focus on MSME, energy security and innovation can translate into a green economy…

16 seconds ago

Trump says US and Russia to start talks on Ukraine war ‘immediately’

Unlock the White House Watch newsletter for freeYour guide to what the 2024 US election…

2 minutes ago

With eye on 2026 Assembly polls, West Bengal govt presents ₹3.89-lakh crore budget

With an eye on the 2026 Assembly elections in the State, the West Bengal government…

9 minutes ago

AI-driven data centres in India to lean on gas-based energy solutions

India’s growing use of artificial intelligence (AI) and a fast expanding digital economy has led…

16 minutes ago

Chevron to slash up to 20% of its workforce

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

19 minutes ago

Natco Pharma’s Q3 net down 37% to ₹132 crore

Natco Pharma’s consolidated net profit declined 37 per cent to ₹132 crore in the third…

22 minutes ago